NASDAQ:MOLN Molecular Partners Q1 2025 Earnings Results & Report $3.85 +0.04 (+1.05%) Closing price 10/9/2026 03:56 PM EasternExtended Trading$3.84 0.00 (-0.13%) As of 10/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Molecular Partners missed analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.50 versus the -$0.3855 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeBefore Market OpensConference Call DateMay 14, 2025Conference Call6:00 PM ET Molecular Partners EPS ResultsActual EPS-$0.50Consensus EPS -$0.3855Beat/MissMissed by -$0.1145One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMolecular Partners Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMolecular Partners' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Molecular Partners Q1 2025 Earnings FAQ Did Molecular Partners beat earnings estimates for Q1 2025? Molecular Partners (NASDAQ:MOLN) reported earnings of -$0.50 per share for Q1 2025, missing the consensus estimate of -$0.3855. The report was announced on Thursday, May 15, 2025. When is Molecular Partners' next earnings date? Molecular Partners' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Molecular Partners on the company's earnings history page. Molecular Partners Earnings HeadlinesContrasting Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)October 7, 2026 | americanbankingnews.comHead to Head Review: AquaBounty Technologies (NASDAQ:AQB) and Molecular Partners (NASDAQ:MOLN)October 5, 2026 | americanbankingnews.comThe Executive Order That Quietly Changed What Your Dollar MeansOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 11 at 1:00 AM | Reagan Gold Group (Ad)Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash BaseAugust 26, 2026 | theglobeandmail.comMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyAugust 25, 2026 | globenewswire.comMolecular Partners Showcases Bispecific Radio-DARPins at Gordon Research ConferenceJuly 15, 2026 | globenewswire.comSee More Molecular Partners Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email. Email Address About Molecular PartnersMolecular Partners (NASDAQ:MOLN) AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines. Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets. The company has also developed antiviral candidates, including ensovibep, a DARPin-based therapy investigated for the treatment of COVID-19. Its pipeline has included internally developed programs as well as candidates advanced through collaborations with pharmaceutical and biotechnology companies. Founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), Molecular Partners serves global pharmaceutical and biotechnology markets through research, clinical development and strategic partnerships. The company’s programs remain subject to clinical testing and regulatory review, and its focus may evolve as development priorities change.View Molecular Partners ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
